ICU MEDICAL INC/DE Q3 FY2024 earnings call

Key Points

• Revenue/Earnings: Q3 revenue $580M, 7% constant currency growth. Adjusted EBITDA $95M, EPS $1.59. Gross margins improved.
• Business Units: Consumables up 9%, IV Systems up 10% constant, Vital Care flat.
• Operations: U.S. and Canada order to cash systems cutover in Q3; focused on optimizing logistics and international activities. Factory consolidations mostly completed by end 2025. Real estate contracts exited/repriced. Quality efforts: majority field corrective actions launched; FDA follow-up inspection at Minneapolis site completed with no observations.
• Joint Venture: Announced strategic JV with Otsuka for IV Solutions. Otsuka brings scale, innovation, financial strength, and global manufacturing footprint to benefit customers with innovation and supply redundancy.

Revenue for Q3 was $580 million, with total company growth of 7% on a constant currency basis or 6% on a reported basis. Consumables grew 9% on both constant currency and reported basis. IV Systems business unit grew 10% constant currency and 7% on a reported basis. Vital Care segment was flat year over year on constant currency and reported basis. Adjusted EBITDA was $95 million and EPS was $1.59. Gross margins were higher than expected due to supply chain efficiencies, FX, and sales mix. Free cash flow was generated, and cash balance increased to approximately $313 million.

Adjusted EBITDA guidance range narrowed and raised to $355M to $365M. Adjusted EPS guidance range raised to $5.40 to $5.70 per share. Q4 gross margins expected 36%-37%, reflecting synergies offset by IV Solutions revenue mix and FX impact.

• Foreign exchange fluctuations can impact results.
• Market concentration in IV Solutions category poses risk.
• Supply chain and manufacturing risks, including potential disruptions.
• Regulatory and compliance risks, especially related to quality and FDA inspections.

Q: Brett Fishbin on strategic thought process of JV and ERP disruption A: Vivek Jain discussed JV as best partner for innovation and customer benefit; Brian Bonnell noted ERP cutover had some volatility but no intra-quarter impact on results.

Q: Eric Fleming on LVP pricing, market share, and peso outlook A: Vivek Jain on LVP pricing focus; market share discussion; Brian Bonnell on peso outlook unclear.

Q: Larry Solow on gross margin, supply chain efficiencies, and JV impact A: Brian Bonnell on supply chain efficiencies ahead of schedule; Vivek Jain on JV margin impact timeline.

Q: Kristen Stewart on IV Solutions manufacturing ramp-up A: Vivek Jain on long-term view, not short-term opportunism.

Q: Mike Matson on JV revenue, sales team, and pump market A: Brian Bonnell on JV P&L impact; Vivek Jain on pump market competition.

Q: Michael Toomey on JV free cash flow and CapEx A: Brian Bonnell and Vivek Jain on neutral to marginally positive free cash flow impact.

Q: Brett Fishbin on JV put call option A: Vivek Jain on put call option details based on revenue multiples, starting fifth year.